Forbes May 16, 2025
The potential of artificial intelligence in pharmaceutical research is intriguing. AI software is making its way into clinical research workflows from predictive analytics through to pharmacovigilance. However, based on new research from global clinical research organization Parexel — and the company’s Chief Business Officer, Keri Mattox — there is a much more important variable determining trial success – humans.
Published Thursday, Parexel’s staffing report provides one of the fullest pictures to date of how the biopharma sector is rising to the challenge of technological disruption. Based on a global survey of 501 professionals, the report looks at where AI is being utilized, what is successful and where talent deficits could hinder advancement.
“There’s an explosion of data across the clinical...
Today's Sponsors
Today's Sponsor